NUMD Nu-Med Plus, Inc. OTC · United States

Nu-Med Plus (NUMD) news

Nu-Med Plus, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker NUMD, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Nu-Med Plus news

We have not published a story on Nu-Med Plus yet. When there is news, it will appear here.

Nu-Med Plus annual financials

Line	FY2025	FY2024
Net income (loss)	-$56,182	-$68,345
Cash from operations	-$47,979	-$4,433
Cash and equivalents	$661	$2,373

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $5,409.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Nu-Med Plus

What is the ticker symbol of Nu-Med Plus?

Nu-Med Plus, Inc. trades under the ticker NUMD on OTC.

Where is Nu-Med Plus listed?

Nu-Med Plus, Inc. is listed on OTC.

Which country or territory is Nu-Med Plus listed under?

Our directory records Nu-Med Plus, Inc. under United States.

Does aibio.space cover Nu-Med Plus?

aibio.space lists Nu-Med Plus, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Is Nu-Med Plus profitable?

Nu-Med Plus, Inc. reported a net loss of $56,182 for the fiscal year ended Dec 31, 2025, and used $47,979 of cash in operations, per its annual report to the SEC.

How much cash does Nu-Med Plus have?

$5,409 in cash at Jun 30, 2026, per its 10-Q.

Investor discussion: Nu-Med Plus

Members talk about Nu-Med Plus (NUMD). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Nu-Med Plus, newest first. Each line links the filing it comes from.

Oct 20, 2026Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Aug 25, 2026Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,9.01). Source
Jul 10, 2026Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,5.01,5.02,5.03,7.01,9.01). Source
Jun 30, 2026Listings
Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:NUMD on TradingView.

Listing details

Company: Nu-Med Plus, Inc.
Ticker: NUMD
Listing: OTC
Country or territory: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction